Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Russian prostate cancer study tracks real-world treatments and genetic clues

NCT ID NCT07052578

Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 19, 2026 · Updated 3 times

Summary

This study observes 400 men in Russia with aggressive, high-volume metastatic hormone-sensitive prostate cancer. Researchers will track which treatments doctors use (like hormone therapy, chemotherapy, or radiation) and test blood samples for genetic mutations. The goal is to understand current care patterns and how genetic testing might guide future decisions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Nov 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

It is planned to enroll approximately 400 patients with high-aggressive (Gleason 8-10) high-volume mHSPC (250 HRRm and 150 HRRwt) with available medical history and known HRRm status in about 30 sites in Russian Federation.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male patients aged ≥ 18 years old; 2. Signed ICF, including consent for blood samples ctDNA and ctDNA-based HRRm testing; 3. Metastatic hormone-sensitive prostate cancer (mHSPC) (de novo or progressed from earlier stages); 4. High-aggressive disease (Gleason 8-10); 5. High-volume disease (according to CHAARTED trial criteria: presence of 4 and more (≥4) bone metastases (including at least one (≥1) outside the vertebral column/pelvis) and/or 1 and more (≥1) visceral metastasis); 6. Availability of source medical documentation; 7. Known HRRm status based on tumour sample evaluation performed in routine practice. Exclusion Criteria: 1. Participation in any interventional trial since the mPC diagnosis. 2. Progression to mCRPC.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic hormone sensitive prostate cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prostate cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    20 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Research Site

    RECRUITING

    Arkhangelsk, Russia

  • Research Site

    RECRUITING

    Barnaul, Russia

  • Research Site

    RECRUITING

    Chelyabinsk, Russia

  • Research Site

    RECRUITING

    Irkutsk, Russia

  • Research Site

    NOT_YET_RECRUITING

    Kazan', Russia

  • Research Site

    RECRUITING

    Krasnodar, Russia

  • Research Site

    RECRUITING

    Krasnoyarsk, Russia

  • Research Site

    RECRUITING

    Moscow, Russia

  • Research Site

    NOT_YET_RECRUITING

    Moscow, Russia

  • Research Site

    WITHDRAWN

    Moscow, Russia

  • Research Site

    RECRUITING

    Nal'chik, Russia

  • Research Site

    RECRUITING

    Nizhny Novgorod, Russia

  • Research Site

    RECRUITING

    Obninsk, Russia

  • Research Site

    WITHDRAWN

    Omsk, Russia

  • Research Site

    NOT_YET_RECRUITING

    Pskov, Russia

  • Research Site

    NOT_YET_RECRUITING

    Saint Petersburg, Russia

  • Research Site

    WITHDRAWN

    Saint Petersburg, Russia

  • Research Site

    NOT_YET_RECRUITING

    Saransk, Russia

  • Research Site

    WITHDRAWN

    Sochi, Russia

  • Research Site

    NOT_YET_RECRUITING

    Syktyvkar, Russia

  • Research Site

    WITHDRAWN

    Tomsk, Russia

  • Research Site

    RECRUITING

    Tomsk, Russia

  • Research Site

    WITHDRAWN

    Tver', Russia

  • Research Site

    RECRUITING

    Tyumen, Russia

  • Research Site

    RECRUITING

    Ufa, Russia

  • Research Site

    RECRUITING

    Yekaterinburg, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.